LAPIX Therapeutics

[{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lapix Therapeutics Inc. Announces a Successful Conclusion of its Pre-IND Meeting Request with the U.S. FDA","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces the Issuance of U.S. Patent for LPX-TI641, Its First-in-Class, Orally Administered Tim3\/4 Agonist for Treg Expansion to Treat Autoimmune Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces FDA Clearance of IND Application for its Treg-expanding Tim3\/4 Agonist LPX-TI641 to Treat Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"LAPIX Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3\/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and other Autoimmune Conditions","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"}]

All Data

Developments

Filters

FILTER:

Company

Sponsor

Country

Therapeutic Area

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

LAPIX Therapeutics Inc. Announces First Subjects Dosed in its First-in-Human Clinical Study of its Treg-expanding Tim3/4 Agonist LPX-TI641 to Treat Multiple Sclerosis and o...

Details:

LPX-TI641, is an orally bioavailable, antigen-agnostic, immune tolerance restoration small molecule that can restore the regulatory T cell/T helper type 17 cell (Treg/Th17) imbalance associated with autoimmune diseases such as MS.

Lead Product(s): LPX-TI641

Therapeutic Area: Neurology Product Name: LPX-TI641

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 07, 2023

ASK
US

Upload
your Pipeline Activity